Event-biased referral can distort estimation of hepatitis C virus progression rate to cirrhosis, and of prognostic influences

Journal of Clinical Epidemiology

Volumn 60, Issue 11, 2007, Pages 1140-1148

  Fu, Bo ^a   Tom, Brian D M ^a   Delahooke, Toby ^b   Alexander, Graeme J M ^c   Bird, Sheila M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^c CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cirrhosis; Hepatitis C virus (HCV); Liver clinic; Progression rate; Referral bias; Simulation

Indexed keywords

ADULT; ALCOHOL CONSUMPTION; ARTICLE; DISEASE COURSE; FEMALE; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PRIORITY JOURNAL; PROGNOSIS; SIMULATION;

ADULT; BIAS (EPIDEMIOLOGY); COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; DISEASE PROGRESSION; FEMALE; GREAT BRITAIN; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; OUTPATIENT CLINICS, HOSPITAL; PROGNOSIS; REFERRAL AND CONSULTATION; RISK ASSESSMENT; SEX DISTRIBUTION; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 35048847446     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2007.01.015     Document Type: Article

References (18)

1. Law M.G., Dore G.J., Bath N., Thompson S., Crofts N., Dolan K., et al. Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. Int J Epidemiol 32 (2003) 717-724
2. Deuffic-Burban S., Wong J.B., Valleron A.-J., Costagliola D., Delfraissy J.-F., and Poynard T. Comparing the public health burden of chronic hepatitis C and HIV infection in France. J Hepatol 40 (2004) 319-326
3. Salomon J.A., Weinstein M.C., Hammitt J.K., and Goldie S.J. Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol 156 (2002) 761-773
4. Hutchinson SJ. Modelling the hepatitis C virus disease burden among injecting drug users in Scotland. PhD Thesis, University of Glasgow; 2004:113-132.
5. Freeman A.J., Dore G.J., Law M.G., Thorpe M., Von Overbeck J., Lloyd A.R., et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 34 (2001) 809-816
6. Bird S.M., Goldberg D.J., and Hutchinson S.J. Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK. Part 2: Preliminary UK estimates of prevalent injection-related hepatitis C carriers, and derivation of progression rates to liver cirrhosis by gender and age at hepatitis C virus infection. J Epidemiol Biostat 6 (2001) 267-277
7. Sweeting M.J., De Angelis D., Neal K.R., Ramsay M.E., Irving W.L., Wright M., et al. Estimated progression rates in three United Kingdom hepatitis C cohorts differed according to method of recruitment. J Clin Epidemiol 59 (2006) 144-152
8. Hutchinson S.J., Bird S.M., and Goldberg D.J. Modelling the current and future disease burden of hepatitis C among injecting drug users in Scotland. Hepatology 42 (2005) 711-723
9. Ferguson N.M., and Donnelly C.A. Assessment of the risk posed by bovine spongiform encephalopathy in cattle in Great Britain and the impact of potential changes to current control measures. Proc Biol Sci 270 (2003) 1579-1584
10. Donnelly C.A., Ferguson N.M., Ghani A.C., and Anderson R.M. Extending backcalculation to analyse BSE data. Stat Methods Med Res 12 (2003) 177-190
11. Stoove M.A., Gifford S.M., and Dore G.J. The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug Alcohol Depend 77 (2005) 81-86
12. Medley G.F., Anderson R.M., Cox D.R., and Billard L. Incubation period of AIDS in patients infected via blood transfusion. Nature 328 (1987) 719-721
13. Report of a Working Group (Chairman: Day NE). The incidence and prevalence of AIDS and other severe HIV disease in England and Wales for 1992-1997: projections using data to the end of June 1992. Communicable Disease Report 3 (1993) S1-S17
14. Multicohort Analysis Project Workshop, Part 1. Immunologic markers of AIDS progression: consistency across five HIV-infected cohorts. AIDS 8 (1994) 911-921
15. Brettle R.P., McNeil A.J., Burns S., Gore S.M., Bird A.G., Yap P.L., et al. Progression of HIV: follow-up of Edinburgh injecting drug users with narrow seroconversion intervals in 1983-85. AIDS 10 (1996) 419-430
16. Collaborative Group on AIDS Incubation and HIV Survival, including the CASCADE EU Concerted Action. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Lancet 355 (2000) 1131-1137
17. Matheï C., Shkedy Z., Denis B., Kabali C., Aerts M., Molenberghs G., et al. Evidence for a substantial role of sharing of injecting paraphernalia other than syringes/needles to the spread of hepatitis C among injecting drug users. J Viral Hepat 13 (2006) 560-570
18. Hallinan R., Byrne A., Amin J., and Dore G.J. Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy. J Gastroenterol Hepatol 20 (2005) 1082-1086